Literature DB >> 9820529

IL-12 enhances antibody responses to T-independent polysaccharide vaccines in the absence of T and NK cells.

R M Buchanan1, B P Arulanandam, D W Metzger.   

Abstract

Polysaccharide vaccines to encapsulated bacteria such as Neisseria meningitidis and Streptococcus pneumoniae are weakly immunogenic due to their T-independent (TI) nature. Even when converted to T-dependent forms through conjugation to foreign proteins, polysaccharides induce responses that are deficient in many respects, such as induction of murine IgG2a Ab, the isotype that mediates optimal complement fixation and opsonization. We now show that IL-12 treatment of mice induces significantly increased levels of IgG2a Ab to the model TI-2 Ag, DNP-Ficoll, and to vaccines composed of polysaccharides from pneumococci and meningococci. Use of immunodeficient mice lacking T cells and/or NK cells demonstrated that such cells were not responsible for the observed Ab enhancement. Furthermore, the use of IFN-gamma knockout mice showed that stimulation of TI-2 Ab responses by IL-12 was only partially dependent on IFN-gamma. The ability of IL-12 to dramatically enhance TI Ab responses suggests that IL-12 will be useful as a powerful vaccine adjuvant to induce protective immune responses against encapsulated pathogens.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9820529

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  14 in total

Review 1.  T lymphocyte dependence of the antibody response to 'T lymphocyte independent type 2' antigens.

Authors:  A Jeurissen; J L Ceuppens; X Bossuyt
Journal:  Immunology       Date:  2004-01       Impact factor: 7.397

2.  Bifidobacterial surface-exopolysaccharide facilitates commensal-host interaction through immune modulation and pathogen protection.

Authors:  Saranna Fanning; Lindsay J Hall; Michelle Cronin; Aldert Zomer; John MacSharry; David Goulding; Mary O'Connell Motherway; Fergus Shanahan; Kenneth Nally; Gordon Dougan; Douwe van Sinderen
Journal:  Proc Natl Acad Sci U S A       Date:  2012-01-23       Impact factor: 11.205

3.  Enhancement of antigen-specific immunoglobulin G responses by anti-CD48.

Authors:  Dorothy Yuan; Yuhong Guo; Suwannee Thet
Journal:  J Innate Immun       Date:  2012-11-27       Impact factor: 7.349

4.  Major carbohydrate antigen of Echinococcus multilocularis induces an immunoglobulin G response independent of alphabeta+ CD4+ T cells.

Authors:  W J Dai; A Hemphill; A Waldvogel; K Ingold; P Deplazes; H Mossmann; B Gottstein
Journal:  Infect Immun       Date:  2001-10       Impact factor: 3.441

5.  Intranasal vaccination with pneumococcal surface protein A and interleukin-12 augments antibody-mediated opsonization and protective immunity against Streptococcus pneumoniae infection.

Authors:  B P Arulanandam; J M Lynch; D E Briles; S Hollingshead; D W Metzger
Journal:  Infect Immun       Date:  2001-11       Impact factor: 3.441

6.  Increased immunogenicity and induction of class switching by conjugation of complement C3d to pneumococcal serotype 14 capsular polysaccharide.

Authors:  S T Test; J Mitsuyoshi; C C Connolly; A H Lucas
Journal:  Infect Immun       Date:  2001-05       Impact factor: 3.441

Review 7.  Interleukin-12 as an adjuvant for induction of protective antibody responses.

Authors:  Dennis W Metzger
Journal:  Cytokine       Date:  2010-07-22       Impact factor: 3.861

8.  Myeloid cell TRAF3 regulates immune responses and inhibits inflammation and tumor development in mice.

Authors:  Almin I Lalani; Carissa R Moore; Chang Luo; Benjamin Z Kreider; Yan Liu; Herbert C Morse; Ping Xie
Journal:  J Immunol       Date:  2014-11-24       Impact factor: 5.422

9.  Adjuvant effects of CpG oligodeoxynucleotides on responses against T-independent type 2 antigens.

Authors:  J Kovarik; P Bozzotti; C Tougne; H L Davis; P H Lambert; A M Krieg; C A Siegrist
Journal:  Immunology       Date:  2001-01       Impact factor: 7.397

10.  Increased protection against pneumococcal disease by mucosal administration of conjugate vaccine plus interleukin-12.

Authors:  Joyce M Lynch; David E Briles; Dennis W Metzger
Journal:  Infect Immun       Date:  2003-08       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.